"Apremilast". 6 Mayıs 2021 tarihinde kaynağından arşivlendi. Erişim tarihi: 26 Kasım 2021.
doi.org
"Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis". The Journal of Rheumatology. 42 (3): 479-88. March 2015. doi:10.3899/jrheum.140647. PMID25593233.
"Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis". The Journal of Rheumatology. 42 (3): 479-88. March 2015. doi:10.3899/jrheum.140647. PMID25593233.
"Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL". Journal of Drugs in Dermatology. 17 (2): 221-228. February 2018. PMID29462231.